Novonordisk's oral weight loss pill NVO.US has been approved by the FDA, entering a new round of the "battle of weight loss pills" with Eli Lilly.

Zhtng Cijng APP noticed that, before the market opened on Tuesday, the stock price of Novo Nordisk (NVO.US) rose by 7.5%, after the Food and Drug Administration (FDA) in the United States approved its weight loss pill. This has given the company a competitive advantage in the rapidly evolving obesity treatment market.